Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton

References

• Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994; 13:5433 - 5441; PMID: 7957109
   PubMed Web of Science ®Google Scholar
• Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274:784 - 787; PMID: 8864119; http://dx.doi.org/10.1126/science.274.5288.784
   PubMed Web of Science ®Google Scholar
• Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 1995; 14:2876 - 2883; PMID: 7796813
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Baldwin AS. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002; 8:385 - 389; PMID: 12127724; http://dx.doi.org/10.1016/S14714914(02)02375-4
   PubMed Web of Science ®Google Scholar
• Kandel ES. NFkappaB inhibition and more: a side-by-side comparison of the inhibitors of IKK and proteasome. Cell Cycle 2009; 8:1819 - 1820; PMID: 19471125; http://dx.doi.org/10.4161/cc.8.12.8966
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505 - 2511; PMID: 12171876
   PubMed Web of Science ®Google Scholar
• Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108 - 2121; PMID: 15169797; http://dx.doi.org/10.1200/JCO.2004.02.106
   PubMed Web of Science ®Google Scholar
• Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006; 66:6379 - 6386; PMID: 16778216; http://dx.doi.org/10.1158/0008-5472.CAN-06-0605
   PubMed Web of Science ®Google Scholar
• Schoof S, Pradel G, Aminake M, Ellinger B, Baumann S, Potowski M, et al. Antiplasmodial thiostrepton derivatives: proteasome inhibitors with a dual mode of action. Angew Chem Int Ed Engl 2010; 49:3317 - 3321; PMID: 20358566
   PubMed Web of Science ®Google Scholar
• Halasi M, Zhao H, Dahari H, Bhat U, Gonzalez E, Lyubimov A, et al. Thiazole antibiotics against breast cancer. Cell Cycle 2010; 9:1214 - 1217; PMID: 20410687; http://dx.doi.org/10.4161/cc.9.6.10955
   PubMed Web of Science ®Google Scholar
• Bhat UG, Halasi M, Gartel A. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS ONE 2009; 4:e5592; PMID: 19440351; http://dx.doi.org/10.1371/journal.pone.0005592
   PubMed Web of Science ®Google Scholar
• Britton M, Lucas MM, Downey SL, Screen M, Pletnev AA, Verdoes M, et al. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol 2009; 16:1278 - 1289; PMID: 20064438; http://dx.doi.org/10.1016/j.chembiol.2009.11.015
   PubMed Web of Science ®Google Scholar
• Pandit B, Gartel AL. Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells. PLoS ONE 2011; 6:e17110; PMID: 21365012; http://dx.doi.org/10.1371/journal.pone.0017110
   PubMedGoogle Scholar
• Pandit B, Gartel AL. New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate 2010; 70:825 - 833; PMID: 20058240
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008; 111:1654 - 1664; PMID: 18006697; http://dx.doi.org/10.1182/blood-2007-08-105601
   PubMed Web of Science ®Google Scholar
• Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol 1998; 153:1239 - 1248; PMID: 9777955; http://dx.doi.org/10.1016/S0002-9440(10)65668-4
   PubMed Web of Science ®Google Scholar
• Wang M, Gartel AL. Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther 2011; In press. PMID: 21903609; PMID: 10.1158/1535-7163.MCT-11-0536
   PubMed Web of Science ®Google Scholar
• Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006; 3:374 - 387; PMID: 16826218; http://dx.doi.org/10.1038/ncponc0555
   PubMedGoogle Scholar
• Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 2011; 3:725 - 731; PMID: 21860463; http://dx.doi.org/10.1038/nchem.1114
   PubMed Web of Science ®Google Scholar
• Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G, et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003; 20:584 - 590; PMID: 12739765; http://dx.doi.org/10.1023/A:1023290514575
   PubMed Web of Science ®Google Scholar